CAR T and Bispecific Antibody Therapies in Multiple Myeloma
Dana-Farber Cancer Institute via YouTube
Get 20% off all career paths from fullstack to AI
AI, Data Science & Cloud Certificates from Google, IBM & Meta
Overview
AI, Data Science & Cloud Certificates from Google, IBM & Meta — 40% Off
One plan covers every Professional Certificate on Coursera. 40% off Coursera Plus Annual.
Unlock All Certificates
In this 42-minute educational video, Dr. Shonali Midha from Dana-Farber Cancer Institute explores the applications of CAR T-cell therapy and bispecific antibody therapy for patients with relapsed/refractory multiple myeloma. Discover the latest developments in immune-based treatment approaches for multiple myeloma, including clinical outcomes, patient selection criteria, and emerging therapeutic strategies. Gain valuable insights into how these innovative immunotherapies are transforming the treatment landscape for patients with this challenging hematologic malignancy.
Syllabus
CAR T and Bispecific Antibody Therapies in Multiple Myeloma
Taught by
Dana-Farber Cancer Institute